On 19 February, we supported Cannabis Europa Paris as a Silver Sponsor, contributing to one of the key conversations shaping the future of medical cannabis in Europe.
As the European cannabis landscape continues to evolve – and with France at a pivotal stage in defining its long-term medical framework – the industry is at a critical juncture. There is increasing recognition that patient-centered cannabis medicines must be underpinned by rigorous pharmaceutical quality, robust clinical evidence, and strong regulatory discipline.
France’s public-health-driven approach reflects a clear ambition: to minimize unnecessary complexity while ensuring patients have access to products that deliver genuine therapeutic value. In this context, Cannabis Europa Paris served as an important platform for constructive dialogue. We were proud to play an active role in these discussions, supported by our quality-focused, pharma-based approach.
We were also honoured that our Scientific Affairs Manager, Nora Rossini, participated as a speaker on the panel “Formats and Product Variety: Limitations vs Options.” The session explored how France can balance regulatory oversight with meaningful therapeutic choices, identify formats that deliver real clinical value, support pharmacist workflows, and draw on
→ Partner with a pharma-driven approach to medical cannabis
Reach out to our team at [email protected] to explore how we can support your product development and regulatory pathway.
→ Stay connected to the evolving cannabis landscape.
Subscribe via the website footer to receive insights from key industry events and regulatory developments across Europe.